These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 34358448)

  • 1. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer.
    Freed-Pastor WA; Lambert LJ; Ely ZA; Pattada NB; Bhutkar A; Eng G; Mercer KL; Garcia AP; Lin L; Rideout WM; Hwang WL; Schenkel JM; Jaeger AM; Bronson RT; Westcott PMK; Hether TD; Divakar P; Reeves JW; Deshpande V; Delorey T; Phillips D; Yilmaz OH; Regev A; Jacks T
    Cancer Cell; 2021 Oct; 39(10):1342-1360.e14. PubMed ID: 34358448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
    Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
    Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
    Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
    [No Abstract]   [Full Text] [Related]  

  • 4. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
    Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
    Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.
    Mu Y; Guan X
    Curr Med Chem; 2024; 31(13):1634-1645. PubMed ID: 38666504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
    Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant
    Nishi K; Ishikura S; Umebayashi M; Morisaki T; Inozume T; Kinugasa T; Aoki M; Nimura S; Swain A; Yoshida Y; Hasegawa S; Nabeshima K; Sakata T; Shirasawa S; Tsunoda T
    Anticancer Res; 2020 Aug; 40(8):4663-4674. PubMed ID: 32727790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD155T/TIGIT Signaling Regulates CD8
    He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
    Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade.
    Pearce H; Croft W; Nicol SM; Margielewska-Davies S; Powell R; Cornall R; Davis SJ; Marcon F; Pugh MR; Fennell É; Powell-Brett S; Mahon BS; Brown RM; Middleton G; Roberts K; Moss P
    Cancer Immunol Res; 2023 Apr; 11(4):435-449. PubMed ID: 36689623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking TIGIT/CD155 signalling reverses CD8
    Liu L; Wang A; Liu X; Han S; Sun Y; Zhang J; Guo L; Zhang Y
    J Transl Med; 2022 Jun; 20(1):280. PubMed ID: 35729552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
    Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
    Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
    Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
    Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD155/TIGIT signaling regulates the effector function of tumor-infiltrating CD8+ T cell by NF-κB pathway in colorectal cancer.
    Li S; Ding J; Wang Y; Wang X; Lv L
    J Gastroenterol Hepatol; 2022 Jan; 37(1):154-163. PubMed ID: 34734434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
    Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
    Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
    Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
    Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
    Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
    Front Immunol; 2021; 12():699895. PubMed ID: 34367161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
    Zhang C; Lin R; Li Z; Yang S; Bi X; Wang H; Aini A; Zhang N; Abulizi A; Sun C; Li L; Zhao Z; Qin R; Li X; Li L; Aji T; Shao Y; Vuitton DA; Tian Z; Wen H
    Hepatology; 2020 Apr; 71(4):1297-1315. PubMed ID: 31410870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.